Abstract Purpose of Review Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting,
angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the …

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Heart failure affects≈ 5.7 million people in the United States alone. Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists …

Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

Abstract Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular
sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin …

Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker. As
an inhibitor of neprilysin, an enzyme that degrades biologically active natriuretic peptides …

It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …

Heart failure is a global problem with elevated prevalence, and it is associated with
substantial cardiovascular morbidity and mortality. Treating heart-failure patients has been a …